Ind-Swift Laboratories Limited Bombay S.E.

Equities

INDSWFTLAB

INE915B01019

Pharmaceuticals

Delayed Bombay S.E. 04:21:57 2024-04-25 am EDT 5-day change 1st Jan Change
124.2 INR +0.85% Intraday chart for Ind-Swift Laboratories Limited +6.64% +19.51%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ind-Swift Laboratories to Incorporate Wholly-Owned Arm in Dubai MT
Ind-Swift Laboratories Limited Announces Incorporation of Wholly Owned Subsidiary CI
Ind-Swift Laboratories Limited Announces Cessation of Sunil Deshmukh as Chief Executive Officer CI
Ind-Swift Laboratories Limited Announces Cessation of Lovekesh Mahajan as Chief Accounts Officer CI
Ind-Swift Laboratories Limited Redeems in Full, the 4245 Rated, Listed, Secured, 10% Coupon, Redeemable, Non-Convertible Debenture CI
Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited and Essix Biosciences Limited. CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
CARE Keeps BB Rating on Ind-Swift Laboratories' Long-term Financing; Rating Under Watch Developing MT
Ind-Swift Laboratories Limited Collaborates with The Council of Scientific and Industrial Research CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Ind-Swift Laboratories Limited agreed to acquire Ind-Swift Limited. CI
Ind-Swift Gets Board Nod to Secure INR6 Billion Loan from Ind-Swift Laboratories MT
India's Ind-Swift Labs to sell pharma ingredients ops for $198.5 million RE
Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 16.5 billion. CI
Ind-Swift Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
RN Chemicals & Pharmaceutical Private Limited acquired Halcyon life Sciences Private Limited from Ind-Swift Laboratories Limited for INR 5 million. CI
Ind-Swift Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Chart Ind-Swift Laboratories Limited
More charts
Ind-Swift Laboratories Limited is an India-based company. The Company is engaged in the business of manufacturing intermediates and formulations. The Company’s products or services include Advanced Intermediates. It is API partner for many organizations both in generic and innovative domains. The Company offers reference standards and impurities for various active pharmaceutical ingredients (APIs) under British Pharmacopoeia (BP), European Pharmacopoeia (EP), British Pharmacopoeia (BP) and others. Its impurity portfolio is stocked with a range of standards for supply. The Company offers reference standards and impurities for over 25 APIs. All impurities are shipped with full documentation, including a Certificate of Analysis and MSDS. The research center, spread over the area of 40,000 square feet, is engaged in developing process technology for APIs in different therapeutic categories.
Calendar
More about the company